Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL2107 vs Keytruda in metastatic non-squamous NSCLC
NCT06754644Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of QL2107 in non-squamous non-small cell lung cancer, sponsored by Qilu Pharmaceutical. Started Jan 2025; status: recruiting.
02
Drugs
QL2107
03
Conditions
non-squamous non-small cell lung cancer
Beyond the preview
Go deeper on NCT06754644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754644.